Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Get Free Report) EVP Charles Wagner, Jr. sold 15,286 shares of the firm's stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $547.87, for a total value of $8,374,740.82. Following the sale, the executive vice president directly owned 31,764 shares of the company's stock, valued at $17,402,542.68. This represents a 32.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Vertex Pharmaceuticals Stock Down 0.2%
Shares of NASDAQ VRTX traded down $0.81 during trading on Monday, hitting $537.79. 1,199,160 shares of the company traded hands, compared to its average volume of 1,392,167. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $412.27 and a fifty-two week high of $568.67. The firm has a market capitalization of $136.35 billion, a price-to-earnings ratio of 34.61, a P/E/G ratio of 2.85 and a beta of 0.28. The business's fifty day moving average is $522.37 and its 200 day moving average is $483.84. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.89 and a current ratio of 2.34.
Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.06). The firm had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.42 billion. Vertex Pharmaceuticals had a net margin of 30.70% and a return on equity of 21.98%. The company's revenue was up 11.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $4.80 EPS. Equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 16.10 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of VRTX. BlackRock Inc. acquired a new stake in Vertex Pharmaceuticals in the 2nd quarter valued at $11,975,849,000. State Street Corp lifted its stake in shares of Vertex Pharmaceuticals by 1.3% in the 3rd quarter. State Street Corp now owns 12,024,456 shares of the pharmaceutical company's stock valued at $6,286,506,000 after purchasing an additional 152,997 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Vertex Pharmaceuticals by 1.1% during the 2nd quarter. Wellington Management Group LLP now owns 3,247,658 shares of the pharmaceutical company's stock worth $1,613,209,000 after purchasing an additional 35,069 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Vertex Pharmaceuticals by 1.0% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,086,683 shares of the pharmaceutical company's stock valued at $1,533,248,000 after acquiring an additional 29,287 shares in the last quarter. Finally, Bank of America Corp DE acquired a new position in shares of Vertex Pharmaceuticals in the second quarter worth $1,509,651,000. Hedge funds and other institutional investors own 90.96% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms have issued reports on VRTX. Weiss Ratings downgraded shares of Vertex Pharmaceuticals from a "buy (b)" rating to a "buy (b-)" rating in a report on Monday, November 9th. Cantor Fitzgerald upped their price target on Vertex Pharmaceuticals from $595.00 to $619.00 and gave the company an "overweight" rating in a research report on Tuesday, November 3rd. Leerink Partners assumed coverage on Vertex Pharmaceuticals in a research report on Monday, September 21st. They set an "outperform" rating and a $594.00 target price on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Vertex Pharmaceuticals from $560.00 to $570.00 and gave the company an "overweight" rating in a research note on Tuesday, November 3rd. Finally, Evercore raised their price target on Vertex Pharmaceuticals from $535.00 to $600.00 and gave the company an "outperform" rating in a report on Wednesday, September 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $596.44.
View Our Latest Analysis on Vertex Pharmaceuticals
Vertex Pharmaceuticals Company Profile
(
Get Free Report)
Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex's CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vertex Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.
While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.